Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | NOS2 | P35228 | 1/20 | 0.56 |
| ▸ | C3AR1 | Q16581 | 10/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CPN1 | P15169 | 1/20 | 0.51 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | GNPAT | O15228 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16748402 | 1.00 | CHRM2 (0.68) | CHRM2CHRM4CHRM1SLC6A5CYP1A2 | |
| Water SCHEMBL30600465 | 0.98 | CHRM2 (0.66) | CHRM2CHRM4CHRM1SLC6A5CYP1A2 | |
| SCHEMBL14117893 | 0.88 | CHRM2 (0.69) | CHRM2CHRM4CHRM1SLC6A5CYP1A2 | |
| SCHEMBL3039364 | 0.84 | CYP2C19 (0.58) | CHRM2CHRM4CHRM1SLC6A5CYP1A2 | |
| SCHEMBL29388277 | 0.84 | CYP2C19 (0.58) | CHRM2CHRM4CHRM1SLC6A5CYP1A2 | |
| SCHEMBL29546257 | 0.83 | CHRM2 (0.64) | CHRM2CHRM4CHRM1SLC6A5CYP1A2 | |
| SCHEMBL13337947 | 0.83 | CHRM2 (0.64) | CHRM2CHRM4CHRM1SLC6A5CYP1A2 | |
| SCHEMBL31110360 | 0.83 | C3AR1 (0.60) | CHRM2CHRM4CHRM1SLC6A5CYP1A2 | |
| Acetic Acid SCHEMBL29358131 | 0.82 | NPY1R (0.59) | CHRM2CHRM4CHRM1SLC6A5CYP1A2 | |
| SCHEMBL1735525 | 0.82 | CYP2C19 (0.65) | CHRM2CHRM4CHRM1SLC6A5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4210763-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2023-07-19 | — | — | EP | claimed |
| WO-2022056277-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2022-03-17 | — | — | WO | claimed |
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250362309-A1 | BIOMARKERS AND USE THEREOF FOR DIAGNOSIS, PREVENTION, AND TREATMENT OF MUSCLE ATROPHY | MYOMAR MOLECULAR INC. (CA) | 2025-11-27 | — | — | US | disclosed |
| US-20250345421-A1 | REDUCING VISCOSITY OF PHARMACEUTICAL FORMULATIONS | AMGEN INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12318447-B2 | Lyophilized powder configured for reconstitution as a liquid pharmaceutical formulation with reduced viscosity and method of preparing thereof | AMGEN INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250169516-A1 | METHODS, DEVICES AND COMPOSITIONS FOR PRESERVING HUMAN MILK | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4557949-A1 | STABLE PLASMIN COMPOSITIONS FOR ORGAN PRESERVATION AND RECONDITIONING | Grifols Worldwide Operations Limited (IE) | 2025-05-28 | — | — | EP | disclosed |
| US-12239142-B2 | Methods, devices and compositions for preserving human milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4452259-A1 | COMPOSITIONS COMPRISING UROLITHIN FOR TREATING MUSCLE DECLINE AND A KIDNEY DYSFUNCTION | Société des Produits Nestlé S.A. (CH) | 2024-10-30 | — | — | EP | disclosed |
| US-20240268402-A1 | Methods, Devices and Compositions for Preserving Human Milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240066124-A1 | REDUCING VISCOSITY OF PHARMACEUTICAL FORMULATIONS | AMGEN INC. (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2024018051-A1 | STABLE PLASMIN COMPOSITIONS FOR ORGAN PRESERVATION AND RECONDITIONING | GRIFOLS WORLDWIDE OPERATIONS LIMITED (IE) | 2024-01-25 | — | — | WO | disclosed |
| US-11813328-B2 | Methods for reducing the viscosity of liquid pharmaceutical formulations comprising therapeutic proteins | AMGEN INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023117659-A1 | COMPOSITIONS COMPRISING UROLITHIN FOR TREATING MUSCLE DECLINE AND A KIDNEY DYSFUNCTION | Société des Produits Nestlé S.A. (CH) | 2023-06-29 | — | — | WO | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-4022052-A1 | METHODS FOR PRODUCTION OF HUMAN RECOMBINANT ARGINASE 1 AND USES THEREOF | Aeglea Biotherapeutics, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022140565-A1 | METHODS AND MATERIALS FOR ASSESSING RADIATION EXPOSURE | NUTECH VENTURES (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-114569716-A | Reducing the viscosity of pharmaceutical formulations | 美国安进公司 | 2022-06-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | LPL, CEL, LPO | CHRM2 1561/4885CHRM4 1465/4885CHRM1 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.